var data={"title":"Atenolol: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Atenolol: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5678?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=atenolol-drug-information\" class=\"drug drug_general\">see &quot;Atenolol: Drug information&quot;</a> and <a href=\"topic.htm?path=atenolol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Atenolol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6172803\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cessation of therapy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Advise patients with coronary artery disease who are being treated with atenolol against abrupt discontinuation of therapy. Severe exacerbation of angina and the occurrence of myocardial infarction (MI) and ventricular arrhythmias have been reported in patients with angina following the abrupt discontinuation of therapy with beta-blockers. The last 2 complications may occur with or without preceding exacerbation of the angina pectoris. As with other beta-blockers, when discontinuation of atenolol is planned, observe the patient carefully and advise the patient to limit physical activity to a minimum. If the angina worsens or acute coronary insufficiency develops, it is recommended that atenolol be promptly reinstituted, at least temporarily. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue atenolol therapy abruptly, even in patients treated only for hypertension.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137426\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tenormin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50594120\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Tenormin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051225\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antianginal Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antihypertensive Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Beta-Adrenergic Blocker</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051219\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=atenolol-drug-information\" class=\"drug drug_general\">see &quot;Atenolol: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosage should be individualized based on patient response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Arrhythmias:</b> Limited data available: Infants, Children, and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Long QT syndrome: Usual range: 0.5 to 1 mg/kg/day either once daily or in divided doses every 12 hours (Kliegman, 2011). In a retrospective trial (n=57; mean age: 9 &plusmn; 6 years) that titrated atenolol to achieve a maximum heart rate less than 150 bpm (Holter monitor and exercise treadmill), higher doses were reported; mean effective dose: 1.4 &plusmn; 0.5 mg/kg/day in 2 divided doses (Moltedo, 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Supraventricular tachycardia: Usual range: 0.3 to 1 mg/kg/day either once daily or in divided doses every 12 hours (Kliegman, 2011, Mehta, 1996; Trippel, 1989). In two separate trials, titration of the dose to &gt;1.4 mg/kg/day did not show additional treatment successes and potentially increased the risk of adverse effects (Mehta, 1996; Trippel, 1989).  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hemangioma, infantile:</b> Limited data available: Infants and Children &lt;2 years: Oral: 1 mg/kg/dose once daily for 6 months; dosing based on a randomized, controlled noninferiority trial compared to propranolol (n=23 total, atenolol treatment group: n=13); atenolol was found to be as effective as propranolol; no significant adverse effects were reported in either group (Abarzua-Araya, 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension:</b> Oral: Children and Adolescents: Initial: 0.5 to 1 mg/kg/day either once daily or divided in doses twice daily; titrate dose to effect; usual range: 0.5 to 1.5 mg/kg/day; maximum daily dose: 2 mg/kg/<b>day</b> not to exceed 100 mg/<b>day</b> (NHBPEP, 2004; NLHBI, 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Thyrotoxicosis:</b> Limited data available: Oral: Children and Adolescents: 1 to 2 mg/kg  once daily; may increase to twice daily if needed; maximum dose: 100 mg/dose (Bahn 2011; Kliegman 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Angina pectoris:</b> Oral: 50 mg once daily; may increase to 100 mg once daily. Some patients may require 200 mg daily. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension:</b> Oral: Initial: 25 to 50 mg either once daily, after 1 to 2 weeks, may increase to 100 mg once daily. Usual dose (ASH/ISH [Weber, 2014]): 100 mg once daily; target dose (JNC 8 [James, 2013]): 100 mg once daily; doses &gt;100 mg are unlikely to produce any further benefit. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postmyocardial infarction: </b>Oral: 100 mg once daily or 50 mg twice daily for 6 to 9 days postmyocardial infarction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing in adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used (Aronoff, 2007): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 0.8 to 1.5 mg/kg/day:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: Maximum dose: 1 mg/kg/dose every 24 hours; maximum daily dose: 50 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: Maximum dose: 1 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: Moderately dialyzable (20% to 50%); maximum dose: 1 mg/kg/dose every 48 hours; give after hemodialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis: Maximum dose: 1 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy: Maximum dose: 1 mg/kg/dose every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt; 35 mL/minute: No dosage adjustment necessary </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 15 to 35 mL/minute: Maximum dose: 50 mg daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;15 mL/minute: Maximum dose: 25 mg daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Moderately dialyzable (20% to 50%); administer dose postdialysis or administer 25 mg to 50 mg supplemental dose after each dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis: Elimination is not enhanced; supplemental dose is not necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, atenolol undergoes minimal hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137398\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tenormin: 25 mg, 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tenormin: 50 mg [DSC] [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tenormin: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137382\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50027149\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=atenolol-drug-information\" class=\"drug drug_general\">see &quot;Atenolol: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Atenolol+SyrSpend SF PH4 oral suspension is available as a compounding kit. Refer to manufacturer's labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051229\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Oral: May be administered without regard to food </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2534078\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051228\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of hypertension, alone or in combination with other agents (FDA approved in adults); management of angina pectoris (FDA approved in adults); post-MI patients (to reduce cardiovascular mortality) (FDA approved in adults); has also been used for management of arrhythmias, infantile hemangioma, and thyrotoxicosis  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137486\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atenolol may be confused with albuterol, Altenol, timolol, Tylenol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tenormin may be confused with Imuran, Norpramin, thiamine, Trovan</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137483\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Bradycardia (persistent), cardiac failure, chest pain, cold extremities, complete atrioventricular block, edema, hypotension, Raynaud's phenomenon, second degree atrioventricular block</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Confusion, decreased mental acuity, depression, dizziness, fatigue, headache, insomnia, lethargy, nightmares </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Constipation, diarrhea, nausea </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Impotence </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Alopecia, dyspnea (especially with large doses), hallucination, increased liver enzymes, lupus-like syndrome, Peyronie's disease, positive ANA titer, psoriasiform eruption, psychosis, thrombocytopenia, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137406\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to atenolol or any component of the formulation; sinus bradycardia; sinus node dysfunction; heart block greater than first-degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; uncompensated cardiac failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Bradycardia (regardless of origin); cor pulmonale; hypotension; severe peripheral arterial disorders; anesthesia with agents that produce myocardial depression; Pheochromocytoma (in the absence of alpha-blockade); metabolic acidosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137386\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse events:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; however, atenolol, with B<sub>1</sub> selectivity, has been used cautiously with close monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conduction abnormality: Consider preexisting conditions such as sick sinus syndrome before initiating.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure (HF): Use with caution in patients with compensated heart failure and monitor for a worsening of the condition (efficacy of atenolol in HF has not been demonstrated).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral vascular disease (PVD) and Raynaud disease: May precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud disease. Use with caution and monitor for progression of arterial obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prinzmetal variant angina: Beta-blockers without alpha<sub>1</sub>-adrenergic receptor blocking activity should be avoided in patients with Prinzmetal variant angina since unopposed alpha1-adrenergic receptors mediate coronary vasoconstriction and can worsen anginal symptoms (Mayer, 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may precipitate thyroid storm. Alterations in thyroid function tests may be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abrupt withdrawal: <b>[US Boxed Warning]: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. </b> Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298790\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137391\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12848&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Some beta-adrenoceptor mediated effects of Alpha-/Beta-Agonists (Direct-Acting), including anti-anaphylactic effects of epinephrine, may be diminished by Beta-Blockers.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<b> Exceptions: </b>Apraclonidine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ampicillin: May decrease the bioavailability of Atenolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bacampicillin: May decrease the bioavailability of Atenolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.<b> Exceptions: </b>Bepridil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives. <b> Exceptions: </b>Nicergoline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and beta-blockers if possible. If coadministration is necessary, patients should have overnight continuous ECG monitoring conducted after the first dose of fingolimod. Monitor patients for bradycardia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Systemic): May increase the serum concentration of Atenolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insulins: Beta-Blockers may enhance the hypoglycemic effect of Insulins. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Anilidopiperidine): May enhance the bradycardic effect of Beta-Blockers. Opioids (Anilidopiperidine) may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reserpine: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives.  Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137421\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Atenolol serum concentrations may be decreased if taken with food. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137394\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137409\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Atenolol crosses the placenta and is found in cord blood. Maternal use of atenolol may cause harm to the fetus. Adverse events, such as bradycardia, hypoglycemia and reduced birth weight, have been observed following in utero exposure to atenolol. Adequate facilities for monitoring infants at birth is generally recommended. The maternal pharmacokinetic parameters of atenolol during the second and third trimesters are within the ranges reported in nonpregnant patients (Hebert 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Untreated chronic maternal hypertension and preeclampsia are associated with adverse events in the fetus, infant, and mother (ACOG 2015; Magee 2014). Although beta-blockers may be used when treatment of hypertension in pregnancy is indicated, agents other than atenolol are preferred (ACOG 2013; Magee 2014; Regitz-Zagrosek 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051224\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, heart rate, ECG, fluid intake and output, daily weight, respiratory rate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137385\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitively blocks response to beta-adrenergic stimulation, selectively blocks beta<sub>1</sub>-receptors with little or no effect on beta<sub>2</sub>-receptors except at high doses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137405\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Beta-blocking effect: Onset: Oral: &le;1 hour; Peak effect: Oral: 2 to 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Normal renal function: Beta-blocking effect: 12 to 24 hours; Antihypertensive effect: Oral: 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid, incomplete (~50%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Low lipophilicity; does not cross blood-brain barrier </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 6% to 16% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Limited hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Beta: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Newborns (&lt;24 hours of age) born to mothers receiving atenolol: Mean: 16 hours; up to 35 hours (Rubin 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents 5 to 16 years of age: Mean: 4.6 hours; range: 3.5 to 7 hours; Patients &gt;10 years of age may have longer half-life (&gt;5 hours) compared to children 5 to 10 years of age (&lt;5 hours) (Buck 1989) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Normal renal function: 6 to 7 hours, prolonged with renal impairment; End-stage renal disease (ESRD): 15 to 35 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Oral: 2 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (50%); urine (40% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051235\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Limited data suggests that atenolol may have a shorter half-life and faster clearance in patients with Marfan syndrome. Higher doses (2 mg/kg/day divided every 12 hours) have been used in patients with Marfan syndrome (6 to 22 years of age) to decrease aortic root growth rate and prevent aortic dissection or rupture; further studies are needed (Reed, 1993).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137404\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>2 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 2 mg/mL oral suspension may be made with tablets. Crush four 50 mg tablets in a mortar and reduce to a fine powder. Add a small amount of glycerin and mix to a uniform paste. Mix while adding Ora-Sweet SF vehicle in incremental proportions to <b>almost</b> 100 mL; transfer to a calibrated amber bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Label &ldquo;shake well&rdquo;. Stable for 90 days at room temperature.</p>\n    <div class=\"reference\">Nahata MC and Pai VB. <i>Pediatric Drug Formulations.</i> 6th ed. Cincinnati, OH: Harvey Whitney Books Co; 2014.</div>\r\n\n    <div class=\"reference\">Patel D, Doshi DH, Desai A. Short-term stability of atenolol in oral liquid formulations. <i>Int J Pharm Compd</i>. 1997;1(6):437-439.<span class=\"pubmed-id\">23989440</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137408\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Atenolol+SyrSpend SF PH4 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (120 mL): $196.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Atenolol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (1000): $776.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1000): $792.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $125.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tenormin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (90): $1,373.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (90): $1,373.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (90): $1,373.76</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137412\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ablok (BR);</li>\n      <li>Alonet (HK);</li>\n      <li>Altol (IN);</li>\n      <li>Angipress (BR);</li>\n      <li>Angiten (LK);</li>\n      <li>Anselol (AU);</li>\n      <li>Antipressan (GB, IE);</li>\n      <li>Apo-Atenol (HK);</li>\n      <li>Arandin (KR);</li>\n      <li>Atarox (PY);</li>\n      <li>Atcord (MX);</li>\n      <li>Atecard (IN);</li>\n      <li>Atecor (IE);</li>\n      <li>AteHexal (DE, NZ);</li>\n      <li>Atehexal (LU);</li>\n      <li>Atelol (BF, BJ, CI, ET, GH, GM, GN, JO, KE, LR, MA, ML, MR, MU, MW, NE, NG, QA, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Atenal (KR);</li>\n      <li>Atendol (DE);</li>\n      <li>Atenex (LK);</li>\n      <li>Ateni (IE, IL);</li>\n      <li>Atenil (CH);</li>\n      <li>Ateno (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Atenobene (HU);</li>\n      <li>Atenocor (RO);</li>\n      <li>Atenodan (DK);</li>\n      <li>Atenodeks (LV);</li>\n      <li>Atenogamma (DE);</li>\n      <li>Atenol (IT);</li>\n      <li>Atenolin (KR);</li>\n      <li>Atenolol Pharmavit (HU);</li>\n      <li>Atenolol von ct (LU);</li>\n      <li>Atenolol-B (HU);</li>\n      <li>Atestad (PH);</li>\n      <li>Atinol (TW);</li>\n      <li>Atoken (MX);</li>\n      <li>Atonium (LB);</li>\n      <li>Atormin (AE, BH, KW, QA, SA);</li>\n      <li>Aveten (MY);</li>\n      <li>B-Vasc (ZA);</li>\n      <li>Betablok (ID);</li>\n      <li>Betacar (CL);</li>\n      <li>Betacard (IN, RU);</li>\n      <li>Betaday (TH);</li>\n      <li>Betaten (QA);</li>\n      <li>Betatop Ge (FR);</li>\n      <li>Beten (LK, MY);</li>\n      <li>Betenol (KR);</li>\n      <li>Biofilen (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Bloket (PY);</li>\n      <li>Blokium (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, GR, HU, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, PY, SA, SC, SD, SL, SN, SY, TN, TZ, UG, VE, YE, ZA, ZM, ZW);</li>\n      <li>Blotex (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Cardioten (PH);</li>\n      <li>Catenol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TH, TN, TZ, UG, ZM, ZW);</li>\n      <li>Corotenol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Durabeta (PH);</li>\n      <li>Enolol (TH);</li>\n      <li>Etnol (BD);</li>\n      <li>Felo-Bits (AR);</li>\n      <li>Hiblok (ID);</li>\n      <li>Hipros (ZW);</li>\n      <li>Hypernol (SG);</li>\n      <li>Hypoten (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Internol (MX);</li>\n      <li>Internolol (ID);</li>\n      <li>Lorten (BD);</li>\n      <li>Lotenac (ID);</li>\n      <li>Lotenal (KR);</li>\n      <li>Myocord (AR);</li>\n      <li>Normalol (IL);</li>\n      <li>Normaten (HK, MY);</li>\n      <li>Normiten (IL);</li>\n      <li>Normocard (PL);</li>\n      <li>Normoten (AE);</li>\n      <li>Nortelol (HK);</li>\n      <li>Noten (AU);</li>\n      <li>Oraday (IN, TH);</li>\n      <li>Ormidol (HR, SI);</li>\n      <li>Paesumex (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Plenacor (BR, CO, EC);</li>\n      <li>Prenolol (SG, TH);</li>\n      <li>Prenormine (AR);</li>\n      <li>Pretenol (MY);</li>\n      <li>Prinorm (HU);</li>\n      <li>Procor (LK);</li>\n      <li>Rotelol (PH);</li>\n      <li>Serten (PH);</li>\n      <li>Stermin (TW);</li>\n      <li>Temoret (ET);</li>\n      <li>Tenamed (LK);</li>\n      <li>Tendiol (EC);</li>\n      <li>Tenoblock (FI);</li>\n      <li>Tenocor (TH);</li>\n      <li>Tenol (ET, SA);</li>\n      <li>Tenoloc (BD);</li>\n      <li>Tenolol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, LU, MA, ML, MR, MU, MW, NE, NG, NZ, SC, SD, SG, SL, SN, TH, TN, TZ, UA, UG, ZA, ZM, ZW);</li>\n      <li>Tenopress (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Tenoprin (FI);</li>\n      <li>Tenoren (BD);</li>\n      <li>Tenormin (AE, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CO, CR, CU, CY, CZ, DE, DK, DO, EE, EG, ES, ET, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, ID, IE, IN, IQ, IR, IT, JM, JO, JP, KE, KR, KW, LB, LK, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, OM, PA, PE, PH, PK, PT, QA, RU, SA, SC, SD, SE, SI, SK, SL, SN, SR, SV, SY, TH, TN, TR, TT, TZ, UG, UY, VE, VN, YE, ZM, ZW);</li>\n      <li>Tenormin ICN (HU);</li>\n      <li>Tenormine (FR);</li>\n      <li>Tenorvas (PH);</li>\n      <li>Tensig (AU);</li>\n      <li>Tensinor (TR);</li>\n      <li>Tensotin (QA);</li>\n      <li>Ternolol (MY);</li>\n      <li>Totamol (HK);</li>\n      <li>Trantalol (IE);</li>\n      <li>Trebanol (MX);</li>\n      <li>Tredol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Urosin (ET, MY, TW);</li>\n      <li>Vascoten (MY, SG);</li>\n      <li>Velorin (MT, MY);</li>\n      <li>Vericordin (AR);</li>\n      <li>Wesipin (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &Aacute;barz&uacute;a-Araya A, Navarrete-Dechent CP, Heusser F, Retamal J, Zegpi-Trueba MS. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study.<i> J Am Acad Dermatol</i>. 2014;70(6):1045-1049. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24656727 /pubmed\" target=\"_blank\" id=\"24656727 \">24656727 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. <i>Pediatrics</i>. 2011;128(5):S1-S44.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Committee on Obstetric Practice. Committee Opinion No. 623: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. <i>Obstet Gynecol</i>. 2015;125(2):521-525. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/25611642 /pubmed\" target=\"_blank\" id=\"25611642 \">25611642 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24150027 /pubmed\" target=\"_blank\" id=\"24150027 \">24150027 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. <i>Endocr Pract</i>. 2011;17(3):456-520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/21700562 /pubmed\" target=\"_blank\" id=\"21700562 \">21700562 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brauchli YB, Jick SS, Curtin F, et al, &quot;Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,&quot; <i>Br J Dermatol</i>, 2008, 158(6):1299-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/18410416/pubmed\" target=\"_blank\" id=\"18410416\">18410416</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buck ML, Wiest D, Gillette PC, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Atenolol in Children,&rdquo; <i>Clin Pharmacol Ther</i>, 1989, 46(6):629-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2598566 /pubmed\" target=\"_blank\" id=\"2598566 \">2598566 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gold MH, Holy AK, and Roenigk HH Jr, &quot;Beta-Blocking Drugs and Psoriasis. A Review of Cutaneous Side Effects and Retrospective Analysis of Their Effects on Psoriasis,&quot; <i>J Am Acad Dermatol</i>, 1988, 19(5 Pt 1):837-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2903871/pubmed\" target=\"_blank\" id=\"2903871\">2903871</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hebert MF, Carr DB, Anderson GD, et al, &quot;Pharmacokinetics and Pharmacodynamics of Atenolol During Pregnancy and Postpartum,&quot; <i>J Clin Pharmacol</i>, 2005, 45(1):25-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/15601802/pubmed\" target=\"_blank\" id=\"15601802\">15601802</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. <i>J Obstet Gynaecol Can</i>. 2014;36(5):416-441.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24927294 /pubmed\" target=\"_blank\" id=\"24927294 \">24927294 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mehta AV, Subrahmanyam AB, Anand R. Long-term efficacy and safety of atenolol for supraventricular tachycardia in children.<i> Pediatr Cardiol</i>. 1996;17(4):231-236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/8662045 /pubmed\" target=\"_blank\" id=\"8662045 \">8662045 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moltedo JM, Kim JJ, Friedman RA, Kertesz NJ, Cannon BC. Use of a cardioselective beta-blocker for pediatric patients with prolonged QT syndrome. <i>Pediatr Cardiol</i>. 2011;32(1):63-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/20960185 /pubmed\" target=\"_blank\" id=\"20960185 \">20960185 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute, National Institutes of Health. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. <i>Clinical Practice Guidelines</i>, 2011. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>. Date accessed: October 2, 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &quot;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&quot; <i>Pediatrics</i>, 2004, 114(2 Suppl 4th Report):555-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/15286277/pubmed\" target=\"_blank\" id=\"15286277\">15286277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed CM, Fox ME, Alpert BS. Aortic biomechanical properties in pediatric patients with the Marfan syndrome, and the effects of atenolol. <i>Am J Cardiol</i>. 1993;71(7):606-608.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/8438752 /pubmed\" target=\"_blank\" id=\"8438752 \">8438752 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2011;32(24):3147-3197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/21873418/pubmed\" target=\"_blank\" id=\"21873418\">21873418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin PC, Butters L, Reynolds B, Evans J, Sumner D, Low RA, Reid JL. Atenolol elimination in the neonate. <i>Br J Clin Pharmacol</i>. 1983;16(6):659-662. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/6661350 /pubmed\" target=\"_blank\" id=\"6661350 \">6661350 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sch&ouml;n MP and Boehncke WH, &quot;Psoriasis,&quot; <i>N Engl J Med</i>, 2005, 352(18):1899-912.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/15872205/pubmed\" target=\"_blank\" id=\"15872205\">15872205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tenormin (atenolol) [prescribing information]. Wilmington, DE: AstraZeneca Pahrmaceuticals LP; October 2012. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trippel DL and Gillette PC, &ldquo;Atenolol in Children With Supraventricular Tachycardia,&rdquo; <i>Am J Cardiol</i>, 1989, 64(3):233-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2741832/pubmed\" target=\"_blank\" id=\"2741832\">2741832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12848 Version 206.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F6172803\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F137426\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50594120\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1051225\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1051219\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F137398\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F137382\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F50027149\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1051229\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F2534078\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1051228\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F137486\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F137483\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F137406\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F137386\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298790\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F137391\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F137421\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F137394\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F137409\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1051224\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F137385\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F137405\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1051235\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F137404\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F137408\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F137412\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12848|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=atenolol-drug-information\" class=\"drug drug_general\">Atenolol: Drug information</a></li><li><a href=\"topic.htm?path=atenolol-patient-drug-information\" class=\"drug drug_patient\">Atenolol: Patient drug information</a></li></ul></div></div>","javascript":null}